Bumps May Grind Female Sex Pill's Sales
This article was originally published in Scrip
Executive Summary
While privately held Sprout Pharmaceuticals has insisted one in every 10 American women have hypoactive sexual desire disorder (HSDD) – meaning there could potentially be several million eligible for the firm's newly approved female sex pill Addyi (flibanserin) – the roadblocks the FDA has thrown up in front of the product could potentially damage its sales, no matter how much hype has revolved around it.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.